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Abstract: Background: Plasmids coding protein aggregation polypeptides from differ-
ent sources have been proposed as genetic adjuvants for DNA vaccines. We reported 
that a plasmid (pATRex), encompassing the DNA sequence for the von Willebrand A 
(vWA/A) domain of the Anthrax Toxin Receptor-1 (ANTXR-1, alias TEM8, Tumor 
Endothelial Marker 8), acts as strong immune adjuvant by inducing formation of in-
soluble intracellular aggregates and subsequent cell death. Objective: In the present study we addressed the question of 
whether there is any substantial immunotoxicity associated with the use of self-aggregating proteins as genetic adjuvants. 
Methods & Results: Here we report, by mean of histology, X-ray and molecular examinations of bone specimens, the un-
expected finding that intramuscular injection of pATRex in mice triggers, per se, severe bone loss (osteoporosis) inde-
pendently from the sex and genotype of the treated animals. Conclusion: Even though the study suggests that proteina-
ceous “sticky “ adjuvants are unlikely to find their way into practical vaccination, the information gained is of value as 
ATRex injections could provide an additional, simplified, mouse model of osteoporosis. Moreover, our results provide 
experimental support to the hypothesis that proteotoxic aggregates chronically activate the innate immune system in amy-
loid and aggregosome associated disorders. 
Keywords: DNA vaccines, Adjuvants, Protein aggregates, Chronic inflammation, Bone remodeling, Osteoporosis. 
INTRODUCTION 
DNA vaccination delivers plasmid DNA encoding the 
target gene to induce both humoral and cellular immune re-
sponses. This strategy has been used for more than two dec-
ades to treat autoimmune disease, viral infection and cancer 
[1]. However, while DNA vaccines have reached clinical 
setting, their use has been in general limited because of their 
restricted ability to induce strong immune responses in 
higher primate and humans [2]. Therefore, DNA vaccines 
will require a new generation of adjuvants for optimal effi-
cacy. However, in any case, one of the major challenges in 
adjuvant research is to gain potency while minimizing toxic-
ity [3]. 
It has been reported that the fusion of antigen-coding 
DNA with genic sequences for protein’s aggregation-
promoting domains from different sources, may enhance the 
antigenic potential of DNA vaccines [4, 5]. In this frame we 
recently demonstrated that a plasmid vector (pATRex)  
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encompassing the DNA sequence for the von Willebrand I / 
A domain (VWA/A) of Anthrax Toxin Receptor-1 (ANTXR-
1, alias Tumor Endothelial Marker 8- TEM8), when co-
administered with different DNA vaccines enhanced immune 
protection against tumors (e.g. Breast cancer, Melanoma) 
and infectious disease (e.g. Malaria) [6, 7]. Further, we got 
evidence that pATRex immune-adjuvancy was related to its 
ability to trigger insoluble intracellular aggregates (aggre-
gosomes) (
*
see foot note), caspases activation (e.g. caspases 
# 9,# 3 and # 12), and apoptotic cell death, leading in turn to 
the stimulation of the innate immune system [7]. In agree-
ment with the notion that aggregosomes preferentially acti-
vate the innate immune system, we found that pATRex in-
jections, without any joint-specific antigen, has no effect on 
the acquired immunosystem as neither B or T cells ATRex-
                                                      
* vWA/A domain, the essential core of pATRex sequence, is a widely dis-
tributed structural module in cell-matrix adhesive proteins, reported to self-
aggregate, and to be involved in multiprotein complexes formation (Whit-
taker CA, Hynes RO. Distribution and evolution of von Willebrand /Integrin 
domains: widely dispersed domain with role in cell adhesions and else-
where. Mol Biol Cell.2002; 13: 3369-87) 
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specfic immunity could be detected after plasmid administra-
tion [6, and unpublished results.] 
An important question to be addressed is whether there 
are any safety issues posed by the use of self-aggregating 
proteins as genetic adjuvants. Could the release of pATRex 
aggregates by dying cells trigger protein aggregation in adja-
cent cells such as occur in prion disease, amyloid and other-
aggregosome disorders? We can also formulate the questions 
of whether the induction of cell death at the injection site or 
wherever else the plasmid distributes in the body may result 
in immune toxicity. The concerns are justified as an associa-
tion between inflammatory disorders and altered protein ho-
meostasis (proteostasis) is now widely recognized. Indeed, 
on one side stands the observation that the products of in-
flammation might impair proteasomes activity leading to 
altered proteostasis and subsequent proteins aggregation [8, 
9]. On the other side, the possibility that aggregates may 
induce inflammation is supported by a plethora of experi-
mental data [10-12]. In this scenario it was hypothesized that 
the persistence of aggregosomes in vivo could initiate a self 
reinforcing cycle of pro-inflammatory signals, ending up in 
chronic inflammation that predisposes the organism to de-
velop a host of systemic diseases (i.e. obstructive pulmonary 
disease, insulin resistance, Paget’s disease of bone, cancer, 
and neurodegenerative diseases) [13]. 
Although our previous studies excluded substantial histo-
pathological changes in a wide array of soft tissues following 
pATRex DNA administration [6], we extended our survey to 
bones. The choice of bone as read-out system for immuno-
toxiciy (a neglected target tissue in studies about the reacto-
genicity of vaccine adjuvants) is based on several considera-
tions: i) Bone is the main supplier of immunocells to in-
flamed tissues, and its exquisitely sensitive to inflammation 
[14]. ii) Bone homeostasis is dinamically influenced by the 
immune system, with lymphocytes and macrophages being 
key mediators of the osteo-immune regulation [15]. As com-
plex and intertwisted, these interactions are ultimately medi-
ated through the effects of bone remodeling, a coordinate 
process between formation and degradation of the bone re-
spectively managed by osteoblasts (OBs) and osteoclast 
(OCs), essentially dictated by a fine-tuned equilibrium be-
tween the pro and anti-inflammatory conditions [16]. iii) 
Wherever chronic inflammatory diseases occurs, systemic 
effect on bone will ensue in bone loss (e.g. osteoporosis) 
[17]. In example, epidemiological studies highlight an asso-
ciation between neurological disorders caused by protein 
aggregates and an increased risk of developing osteoporosis: 
Parkinson Disease [18-20], Huntington Diseases [21-23], 
and Alzheimer Disease [24, 25]. Notably, amyloid  peptides 
from Alzheimer’s patients have been reported to accumulate 
in osteoporotic bone tissue and to enhance osteoclast func-
tion [26]. iv) Finally, relevant to our work, there are reports 
about the ability of i.m injected plasmids to reach the bone 
marrow, and to be acquired by resident immunocells (i.e. 
neutrophils or monocytes) [27, 28]. 
Here we report that the delivery of pATRex in healthy 
mice, by uncoupling bone formation from bone resorption 
leads to a fast and severe inflammatory bone loss. 
MATERIALS & METHODS 
DNA Plasmids 
For DNA immunizations, large scale preparation of the 
plasmids was routinely performed by alkaline lysis using 
Qiagen Plasmid Maxi kits (Qiagen). To assure endotoxin 
free products, DNA plasmids were purified using either 
Endo Free Plasmid Kit (Qiagen) or Gen Elute HPSelect 
Plasmid Giga Prep columns (Sigma # NA0800). 
Animals Trials 
Female and male FVB and Balb/c mice (Harlan Italy SrL, 
Correzzana Milano, Italy) were used. Mice were kept in 
laminar-flow cage in a standardized environmental condi-
tion. Mice (6-8 weeks old) were randomized in four sub-
groups (six mice for each subgroup) and injected intramus-
cularly (i.m.) into the hind limb at week 0, 1, 2. Each mouse 
received at a time 100 μg of DNA (1 mg/ml) in saline using 
an insulin syringe; the subgroups were as follows: subgroup 
1: 100 μg pcDNA3.1- ATRex (experimental); subgroup 2: 
100 μg pANTXR-1 (control, coding for the parental 
ANTXR- 1, alias TEM8) subgroup 3: 100 μg pcDNA3.1 
(scaffold plasmid); subgroup 4: only saline. At the end of 
these injection cycles, mice from all groups were sacrificed 
at 90th days after the first injection to monitor the impact of 
plasmids on bone homeostasis. All mice were sacrificed by 
CO2 narcosis according to the recommendation of the Italian 
Ethical Committee and under the supervision of authorized 
investigators. To evaluate the systemic effects of the injec-
tion sites, plasmids were injected either into the left or right 
quadriceps, and counter-lateral bone collected. 
Histological Examination 
Femurs, dissected from adhering tissue, were fixed in 4% 
paraformaldehyde (PFA) and decalcified as previously de-
scribed [29]. Samples, were embedded with Tissue-Tek OCT 
compound (Sakura). Then, 12 μm thick sections of femurs 
were obtained by a rotatory -30°C microtome cryostat (Ames 
Cryostast Miles), air-dried and stained with toluidine blue or 
hemotoxylin-eosin. Digital-assisted bone immage analysis 
was performed as previosely described [30]. Briefly, a black 
and white image mask was constructed. A region of interest 
was selected from a Toluidine blu-stained section. This im-
age was then Adobe Photoshop™ to prepare the black-and-
white mask. Within the selected region of interest, trabecular 
bone was identified and represented in black.  
Osteoclasts were stained by Acid Phosphatase, Leuko-
cyte (TRAP) kit (Sigma-Aldrich, Milano, Italy) according to 
the manufacturer’s instructions. Quantification of the TRAP-
stained area per 0.3 x 0.3 mm
2
 under the growth plate of the 
proximal femur was performed using NIH ImageJ as previ-
ously described [31]. 
Other sections were stained with freshly prepared Oil 
Red O. Sections Images were captured by a Leica DM 2500 
optical microscope.  
X-ray Analysis 
After anesthesia with isoflurane-air mixture, mice were 
positioned in dorsal recumbence, making sure that pelvis, 
femurs and tibias were included in radiographs. A portable 
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X-ray generator (Gierth HF 80/15 plus ULTRA LEICH, 
Gierth X-Ray International GmbH, Germany) mounted on a 
stative with focal distance of 60cm was used; X-ray applied 
dose was 54Kv for a time of 0.04sec. Radiographs were ac-
quired in DICOM format with Fujifilm FCR Capsule X (Fu-
jifilm Corporation, Japan) and processed both with Osirix 
(Pixmeo SARL, Switzerland) and ImageJ (http:// 
rsb.info.nih.gov/ij/) software, according to image analysis 
protocols previously reported [32, 33]. Long bones were first 
processed in Osirix for region of interest (ROI) identifica-
tion; afterward, the DICOM images were converted with 
ImageJ into TIFF images and a 16 intervals pseudo-color 
scale was applied to the grey scale. This scale starts from 
black pixels (value of zero) and increasing gradations of 
mineralization density are represented in 16 equal intervals 
by a pseudo-color scheme to white pixels (value of 255). 
Hence, distribution of pixels in a ROI was calculated and 
displayed as a histogram. 
Western Blotting 
Long bones (femurs, tibiae and humeri) from the above 
mouse groups were dissected free of adhering tissue. The 
ends were removed, and the marrow cavity was flushed with 
DMEM. Western blotting was performed as previously de-
scribed [34]. Membranes were incubated with the following 
primary antibodies diluted in blocking buffer: rabbit anti-
Osteoprotegerin and mouse anti-RANKL antibodies (Ab-
cam, Prodotti Gianni, Milano, Italy) diluted respectively 
1:500 and 1:250; rabbit mAb anti-Runx-2 antibody (Cell 
Signaling, Euroclone, Milano, Italy) diluted 1:800; rabbit 
anti-Osterix antibody (Santa Cruz Biotechnology, Italy) di-
luted 1:600, rabbit anti-NF-kB and rabbit anti-TNF-a diluted 
1:500 (BioLegend, Microtech SrL, Napoli, Italy). After wash-
ing blots were incubated with horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit IgG or with HRP-conjugated 
rabbit anti-mouse IgG (Cell Signaling, Euroclone Milano, Italy) 
both diluted 1:50,000 in blocking solution for 1 h at RT. To 
normalize the bands, filters were stripped and reprobed with a 
monoclonal anti--tubulin (Sigma-Aldrich, Milano, Italy). 
Bands density was quantified by densitometric scan. 
Real Time PCR 
Total RNA was extracted in TRIZOL reagent (Invitrogen 
Life Technologies, CA) from mice bone marrow obtained as 
above described. cDNA was synthesized using RevertAid H 
Minus First Strand cDNA Synthesis Kit (Thermo Scientific, 
MA) according to manufacturer’s protocol. PCR primers are 
listed as follows: 
collIFW, 5’-GGAAGAGCGGAGAGTACTGGATC-3’ and 
collIRev, 5’-TACTCGAACGGGAATCCATCGGT-3’ ; 
OCNFW, 5’-TCTGACCTCACAGATGCCAAGCCC-3’ and 
OCNRev, 5’-TAGGCGGTCTTCAAGCCATACTGG-3’; 
MOUSEactinFW, 5’-TTCGTTGCCGGTCCACA-3’ and 
MOUSEactinRev, 5’-ACCAGCGCAGCGATATCG-3’. 
Real time PCR was performed in three replicates of each 
sample using DyNAmoTM Flash SYBR Green
®
 qPCR Kit 
(Thermo Scientific, MA) on a Stratagene Mx3000P; each 
reaction tube contained a total of 50 ng of cDNA into 20 μl 
of total reaction volume. Actin gene expression was used as 
internal control to normalize the amount of target cDNA 
added to the reactions. Data are expressed as fold change of 
gene expression relative to empty vector injected mice. 
Statistical Analysis 
GraphPad Prism 5.0 for Macintosh was used for drawing 
graphs and for statistical analysis 
(GraphPad Software, San Diego, CA, USA). All in vitro 
and in vivo experiments were repeated at least three times. t-
student test was used to test for significant differences  
(p< 0.05) between two groups. 
RESULTS & DISCUSSION 
The inflammatory potential (reactogenicity) of vaccine 
adjuvants on bone structure / homeostasis has been never 
documented. In this study we evaluated the impact of pA-
TRex DNA administration on bone physiological remodel-
ing. In our experiments, mice were i.m. injected for three 
weeks (once a week) either with pATRex or control plasmids 
(pANTRX-1 or sham pcDNA 3.1 vector), and sacrificed 
three months after the first injection (see Material & Meth-
ods section for details). Afterwards bones were isolated and 
routinely analyzed for osteo-toxicity by standard techniques. 
What follow are representative results as obtained from 
independent trials (three for each selected plasmid) in female 
Balb/c mice. Notably, the results were consistently repro-
duced in male Balb/c, and in FVB/N mice strain of both 
sexes (Data available on request). 
Inflammatory Bone Loss: Histological, X-ray & Molecu-
lar Evidences 
Femurs from plasmids injected mice were collected for a 
first histological evaluation. As shown in Fig. (1) mid 
diaphysis femurs from pATRex-treated mice evidenced, at 
variance of control ANTXR1 plasmid treated mice, a dra-
matic loss of cortical bone resulting in deep and extended 
cavities suggestive of an enhanced bone resorpting activity. 
Moreover the analysis of the metaphyseal regions of the dis-
tal femurs also evidenced bone erosion and thinned discon-
nected trabeculae Fig. (2A), whose area was significantly 
reduced as assessed by digital-assisted bone image analysis 
[30] (Fig. 2B). Even though that these basic histological ob-
servations, per se, do not allow an accurate quantitative 
analysis of trabecular and cortical changes, as obtained by 
using either software-assisted histomorphometry or X-ray 
microtomographic (μCT), they high reproducibility over a 
large number of sections and animals examined decidedly 
demonstrates that pATRex injections selectively induce bone 
resorption. 
Additionally, we got evidence that pATRex administra-
tion significantly deteriorated bone mineral and organic ma-
trices (bone density). Indeed, while X-ray scanning evi-
denced an important demineralization (approx. 25 % com-
pared to control ANTXR1 plasmid treated mice) Fig. (3 A, 
B), quantitative real time-RT PCR analysis demonstrate a 
down-regulation of both Collagen I (that accounts for ap-
prox.90% of organic matrix) and osteocalcin mRNAs ex-
pression, the latter been considered an important marker of 
bone formation (Fig. 3C) [35]. 
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Fig. (1). Representative sections toluidine bleu stained of femur mid diaphyses from pATRex DNA (A, B) and ANTXR1 DNA-injected mice 
(C). Arrows indicate resorption cavities within the cortex, and arrows head point to osteoclastic activity. Magnifications: 40x (A, B); 20x (C). 
Number of mice examined (N) = 7 per group. 
 
 
Fig. (2). Representative reconstruction toluidine bleu stained of metaphyseal regions of distal femurs from ANTXR1 DNA and pATRex 
DNA-injected mice (A). Representative reconstructions opened in Adobe Photoshop
®
 to prepare the black and white mask. Bone was identi-
fied and represented in black. Trabecular bone area quantification was performed by Image J software. Statistical analysis derives from six 
independent measurements of the trabecular bone area (B); *p<0.05 N = 7 per group. 
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Fig. (3). X-ray images of pelvis and hind limbs of animals of the experiment. Areas of ROI are indicated (small ellipses). Histograms of bone 
density measured at the levels of distal epiphysis, diaphysis and proximal epiphysis from the original 16 bit DICOM X-ray radiographs (A). 
Pseudo-color images of pelvis and hind limbs of the same X-ray images, obtained converting to an 8 bit TIFF format from the original 16 bit 
DICOM X-ray radiographs and pseudocoluring the resultant image using a 16 color look-up table. Histogram of grey levels frequency within 
subchondral bone ROI (B). N = 7 per group. Gene expression of collagen I and osteocalcin by Real-Time PCR from whole bone marrow (C). 
The pathological (resorptive) scenario induced by pA-
TRex injections can be rationally traced back to an increased 
OCs activity, coupled with an impaired OBs differentiation. 
Indeed, an increased OCs activity can be documented by a 
remarkable increase of tartrate resistant acid phosphatase 
(TRAP) staining around the trabeculae (Fig. 4 A-D) [36]. On 
the other hand, an impaired OBs differentiation in pATRex-
treated mice is highlighted by the presence of fat cells (adi-
pocytes) within the bone marrow cavity, at the sub-
metaphyseal region (Fig. 4 E-H). 
It is well established that fatty infiltrations characterize 
the process of bone loss due to an impaired mesenchymal 
stem cells (MSCs) differentiation, which results in decreases 
maturation of OBs in favor of an increased adipocytes differ-
entiation [37, 38]. Coherently with an elevated adipogenic
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Fig. (4). Epiphyseal regions of distal femurs from ANTXR1 DNA (A) and pATRex DNA-injected mice stained with TRAP (B, C). Magnifi-
cations: 20x (A, B); 40x (C). Quantification of TRAP-positive stained area under growth plate of proximal femur per field (0.3x0.3 mm
2
). 
Representative reconstruction of metaphyseal regions of distal femurs from pATRex DNA-injected mice stained with hematoxylin-eosin (E, 
F), emphasizing areas enriched in adypocites. Oil red staining (G, H). Magnifications: 20x (E-H). N = 6 per group. (I) Representative western 
blotting of PPAR from total bone marrow cells obtained from ANTXR1 DNA and pATRex DNA-injected mice (I). Statistical analysis, de-
riving from three independent experiments, shows increased PPAR synthesis in bone marrow cells from pATRex DNA-injected mice; 
*p<0.05. N = 6 per group. 
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potential of MSCs in pATRex treated bone, we recorded a 
strong up-regulation of a master moderator of adipogenesis, 
such as peroxisome-proliferator-activated receptor- (PPAR-
) transcription factor (Fig. 4 I) [39, 40]. 
Fully consistent with the morphological studies, were the 
results obtained by the analysis of the expression of bio-
chemical markers of the bone turnover in bone marrow-
derived stromal cells (BMSCs). Classically, Receptor Acti-
vator of NF-B ligand (RANKL) and TNF- are master in-
flammatory cytokines, that by enhancing the expression of 
NF-kB, regulate bone homeostasis by the concomitant stimu-
lation of osteoclastogenesis and inhibition of osteoblast func-
tion [41]. It has also been reported that RANKL can induce 
the differentiation of monocytes and macrophages to 
preosteoclasts [42]. On the other hand, TNF- its well 
known to inhibit osteoblast differentiation on multiple levels 
[43, 44] and its overexpression drives to significant focal and 
systemic bone erosions. Accordingly, BMCs from pATRex-
injected mice showed a marked up-regulation of both TNF 
and NF-kb (Fig. 5A). In addition, we also observed increased 
levels of RANKL expression, while osteoprotegerin (OPG), 
the soluble (decoy) receptor that inhibits RANKL activity 
[45] was not affected (Fig. 5B). Moreover, (in line with data 
in Fig. 3C) Runx-2 and Osterix, key transcription factors for 
osteoblast differentiation [46, 47], were decreased by pA-
TRex treatment (Fig. 5B). 
Although we have not direct evidence of the deposition 
of pATRex aggregates in the osteoporotic bone, future stud-
ies will address this issue by immunofluorescent /confocal 
laser microscopy of EYFP-conjugated pATRex injected 
plasmid [7]. Moreover, since plasmids biodistribution might 
change with the administration routes, studies are also 
planned to explore the osteoporotic potential of pATRex 
following gene-gun delivery and /or intraperitoneal injection. 
In the latter case the inoculum introduced into the body cav-
ity, instead of forming a localized deposit, it may spread out 
and induce disseminated reactions. 
CONCLUDING REMARKS 
In summary, the evidence presented here points to a pre-
viously unrecognized “hidden” reactogenicity (bone erosion) 
of pATRex-derived aggregates. Thus, while the study casts 
doubts about the clinical use of pATRex as vaccine adjuvant, 
it reminds us that great caution should be exercised in re-
spect to adjuvants postulated to work via cellular toxicity and 
cell death. Our results provide experimental support to the 
hypothesis that highly stable protein aggregates in neurode-
generative proteinopathies and other aggregosome disorders, 
are recognized as dangerous “non self ” particles that chroni-
cally activate the innate immunosystem. Whether the injec-
tion of plasmids coding known pathological aggregate-
inducing sequences (e.g. A42 and mutant huntingtin poly-
peptides) induces comparable osteo-immunotoxicty remains 
 
Fig. (5). BMCs were obtained from ANTXR1 DNA and pATRex DNA-injected mice. Note the statistically significant increase of TNF and 
NFkB (A) as well as RANKL protein levels after pATRex DNA treatment, over unchanged OPG, and decreased Runx-2 and OSX transcrip-
tion levels (B). *p<0.05. N = 7 per group. 
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to be seen. Lastly, beyond this cautionary note, and open 
questions about the clinical relevance of inflammatory ag-
gregates, we propose pATRex-injected mice as an additional, 
simplified, mouse model of osteoporosis [48] for the evalua-
tion of mayor pharmaceuticals and novel biodrug candidates. 
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